Subsequently, another study revealed that the reversal of STING methylation in mouse melanoma cell lines using a clinically available DNA methylation inhibitor, decitabine, ameliorates STING agonist-induced activation and IFN-I induction, thereby enhancing the CD8+ T-cell-dependent immune response that promotes tumor regression [103]. Here, CD8A is linked to melanoma.